Recession fears have a way of making income investors second-guess everything, and if dividends are paid out of cash flow, and cash flow shrinks during economic downturns, it only seems logical that ...

Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Defensive Dividend Stocks for 2025. On March 3, BofA analyst Jason Gerberry raised the firm’s price recommendation on Johnson & Johnson (NYSE ...

Volatility is again picking up, and it’s a good idea to focus more on safety. There’s no better way to do so than to buy ...

If you are wondering whether Johnson & Johnson is still fairly priced after its recent run, this article will help you weigh what you are paying against what you are getting. The stock last closed at ...

Intuitive Surgical (ISRG) remains the robotic-assisted surgery market leader, with Q4 procedures up 18% and revenue rising 19% to $2.87 billion.

Wednesday, March 11, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan ...

With a market cap of $592.4 billion, New Brunswick, New Jersey-based Johnson & Johnson (JNJ)is a global healthcare company engaged in the research, development, manufacturing, and sale of a broad ...

In early March 2026, Johnson & Johnson received U.S. FDA approval for TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to treat adults with relapsed or refractory ...

Johnson & Johnson is a Dividend King. Its size and breadth have allowed it to flourish despite the many changes in the healthcare space over the years. Its total return over the past decade tops 200%.

Johnson & Johnson stock is boring -- in a good way.